Non-viral targeted
gene insertion technology
Our Mission
Enabling the Future of Genome Engineering
KOMO’s mission is to enable the next generation of biological innovation by developing non-viral platforms for precise DNA insertion. Through targeted integration of large genetic payloads, KOMO gives developers greater control over where, how, and what is added to the genome, making it possible to build more complex, scalable, and predictable biological systems.
Through its KOMbine™ and KOMbineX™ platforms, KOMO empowers partners across therapeutics, bioprocessing, agriculture, and industrial biotechnology to address complex global challenges with greater speed, consistency, and confidence.
chromosome
per cell
Our Science
KOMbine™ Gene Integration Technology Platform
KOMbine™ is a next-generation, precision genome engineering platform that utilizes proprietary hyperactive integrase to insert large DNA payloads precisely and efficiently into a wide range of cell types—including CHO, HEK, and iPSCs—without the need for clonal selection.
Through the use of high-efficiency, site-specific integrases as a precision genome engineering tool, KOMbine™ aims to address limitations of current genome engineering methods with respect to off-target editing, low efficiency, and inability to insert large fragments of DNA.
KOMbine™ is non-viral and does not rely on unprotected double-strand DNA breaks.
Whether you’re manufacturing antibodies, engineering cell and gene therapies, or building next-gen biologics, KOMbine™ enables targeted, efficient, and reproducible delivery of large genetic payloads.
Our Science
Precision Genome Engineering
Meet KOMO FT™ —an innovative and proprietary cell line platform utilizing highly evolved hyperactive integrases that can insert large genes into a specific site in the human genome at 80% efficiency per chromosome and up to 96% efficiency per cell—without the need for unprotected double-strand DNA breaks.
KOMO BIOSCIENCES’ platform has the potential for broad application in cell line development, biologics, advanced therapies manufacturing, and pandemic preparedness.
News & Media
KOMO Announces Research License Agreement with Caravan Biologix
Top media outlets highlight the strategic collaboration and the promise of the KOMbine™ gene editing platform.
KOMO Biosciences and Syngenta Partner to Explore Precision Genome Modification in Maize
KOMO Biosciences Strengthens Strategic Leadership with New Advisory Board Appointments
KOMO Biosciences Appoints Patient Advocate Tom Whitehead and Immunotherapy Pioneer Michael Kalos, Ph.D. to Advisory Board
Get In Touch
Contact us to learn more about KOMO
and/or share your program needs.